Showing 291-300 of 10606 results for "".
Lupus erythematosus tumidus vs Jessner's lymphocytic infiltrate of the Skin
https://practicaldermatology.com/topics/general-topics/lupus-erythematosus-tumidus-vs-jessners-lymphocytic-infiltrate-of-the-skin/21686/A systematic comparison of clinical and histologic characteristics.Comorbidities in Hidradenitis Suppurativa
https://practicaldermatology.com/issues/march-2025/comorbidities-in-hidradenitis-suppurativa/33164/Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterized by inflamed abscesses, nodules forming tunnels that can lead to scarring in intertriginous areas.Topical Treatments for Hidradenitis Suppurativa
https://practicaldermatology.com/topics/rare-disease/topical-treatments-for-hidradenitis-suppurativa/56433/Topical therapies can provide benefit by reducing bacterial burden, decreasing inflammation, and providing symptomatic relief from minor localized flares.Biologics for Psoriasis: A Status Update
https://practicaldermatology.com/topics/psoriasis/biologics-for-psoriasis-a-status-update/23006/The field has grown substantially from the early 2000s to include now a dozen innovator systemic agents, a host of biosimilars, and soon JAK Inhibitors.The Benefits of Private Practice: A Q&A with Joel Schlessinger, MD, FAAD
https://practicaldermatology.com/issues/september-2025/the-benefits-of-private-practice-a-qa-with-joel-schlessinger-md-faad/37630/While selling to and working for private equity–backed platforms may have its perks, many long-time private practitioners warn that the advantages of private practice are often not fully appreciated until it is too late. Practical Dermatology Chief Cosmetic Surgery Editor Emeritus Joel Schlessinger,Melanoma in Skin of Color: More to Learn
https://practicaldermatology.com/topics/skin-cancer-photoprotection/melanoma-in-skin-of-color-more-to-learn/23486/With evidence showing that cumulative UV exposure is not strongly correlated with melanoma risk in patients with skin of color, dermatologists must re-consider their messaging.Mineral Sunscreens with Iron Oxides are Underused for Dyschromia in Skin of Color
https://practicaldermatology.com/topics/skin-of-color/mineral-sunscreens-with-iron-oxides-are-underused-for-dyschromia-in-skin-of-color/23697/A local survey highlights the opportunity for dermatologists to counsel and educate skin of color patients on the use of tinted mineral sunscreens for bothersome dyschromia.Choosing or Evaluating Your Advisors: 3 Mistakes to Avoid
https://practicaldermatology.com/issues/august-2025/choosing-or-evaluating-your-advisors-3-mistakes-to-avoid/36707/If the recent inflationary economy, high interest rates, and market volatility have caused you to adopt a new or renewed focus on financial matters, you are not alone. Perhaps you are planning to seek help from a professional advisor for the first time, considering changing or re-evaluating your curDermWireTV: Derm Salaries Down, Allergan Eyes Soliton, Emsculpt Week
https://practicaldermatology.com/topics/practice-management/dermwiretv-derm-salaries-down-allergan-eyes-soliton-emsculpt-week/19941/Just under half of all physicians in the US are employed in physician-owned medical practices, new data from the American Medical Association show. Medscape’s annual Physician Compensation Report reveals that physicians overall saw a reduction in income due to the COVID-19 pandemic; income for dermDermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)